Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting

1 Oct 2017

Abstract excerpt

Background: Non small cell lung cancer (NSCLC) is diagnosed in most cases on small tissue samples, such as cytological preparations and histological biopsies; these limited tissue specimens may be not always sufficient for testing epidermal growth factor receptor (EGFR) mutations and other relevant predictive biomarkers. Cell-free DNA (cfDNA) can be used as a surrogate for EGFR mutational testing, whenever tissue...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29184677
DOI: 10.21037/jtd.2017.06.97

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal settingPMID 29184677Read ↗

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.Semantic proximity Read ↗

Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samplesSemantic proximity Read ↗

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challengesSemantic proximity Read ↗

Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic.Semantic proximity Read ↗

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal settingSemantic proximity Read ↗

Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.Semantic proximity Read ↗

Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patientsSemantic proximity Read ↗

Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.Semantic proximity Read ↗

Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: a retrospective study.Semantic proximity Read ↗

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancerSemantic proximity Read ↗

Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.Semantic proximity Read ↗

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.